Duopharma to deliver a satisfactory performance in 2024


KUALA LUMPUR: Duopharma Biotech Bhd aims to deliver a satisfactory performance in 2024, underpinned by the positive advancements and anticipated growth in the economy and industry.

In a filing with Bursa Malaysia, the pharmaceutical company noted that it had encountered a myriad of challenges in 2023 which exerted pressure on its manufacturing margins, thus influencing the group’s overall profitability in 2023.

5.5 PAYDAY OFFER: 35% OFF Digital Access

Monthly Plan

RM 13.90/month

RM 9.04/month

Billed as RM 9.04 for the 1st month, RM 13.90 thereafter.

Best Value

Annual Plan

RM 12.33/month

RM 8.02/month

Billed as RM 96.20 for the 1st year, RM 148 thereafter.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!
Duopharma , pharmaceutical

Next In Business News

Scanwolf wins RM6mil industrial development job
Country Heights to take over Mines Beach Resort after agreement termination
Manulife Malaysia launches MultiCI Enrich to address evolving critical illness needs
TDM unit appoints GPQ for RM 142.8mil medical centre project in Terengganu
Marine & General appoints Abdul Hafidz as JMM's new CEO effective May 1
KPS Consortium to acquire industrial properties for RM45.5mil
Ringgit closes lower on volatile oil prices, latest Fed decision
CIMB Niaga posts 1Q profit before tax of 2.3 trillion rupiah
Mitrajaya Trading emerges as substantial shareholder in Mitrajaya
Pasdec appoints Mohammad Ikhwan as CEO effective May 1

Others Also Read